adjuvanted recombinant zoster vaccine (rZV) Protects against herpes zoster (shingles) and associated complications like post herpetic neuralgia. tabsOverview Shingrix® is approved for use for the prevention of herpes zoster (shingles) and herpes zoster complications such as post herpetic neuralgia (PHN) in adults aged over 50 years. PHN is a debilitating and painful condition, particularly in older people. It is recommended, but not funded, for all individuals aged from 50 years. It is particularly recommended for individuals have an increased risk of zoster and zoster complications and for those who have contraindications to the live zoster vaccine (Zostavax). The effectiveness of this vaccine does not decrease when given to older age groups (with an efficacy of around 90% against zoster and PHN), so those aged over 70 years will also be protected and a high level of protection (over 80%) has been shown to be maintained for more than seven years, so far. Shingrix is an adjuvanted subunit vaccine that contains recombinant VZV glycoprotein E (gE). Unlike the live attenuated zoster vaccine, Zostavax, it is a non-live vaccine that can be given to people who are immunocompromised or receiving immunosuppressive treatments. The proprietary adjuvant (AS01B) enhances the neutralising antibody and specific T cells responses against VZV. Please see the below links for more information.
Responses to vaccine
References
Other brands: also available for protection against zoster is a live attenuated zoster vaccine - Zostavax Vaccine type: adjuvanted subunit protein vaccine Schedule and administrationShingrix is approved for the prevention of herpes zoster (shingles) and its associated complications, including post herpetic neuralgia (PHN). It may be purchased by adults aged from 50 years. Although a live attenuated zoster vaccine Zostavax, is funded at the age of 65 years, many adults have medical conditions that increase their risk for zoster or are, with advancing age, at higher risk of PHN and other debilitating complications associated with zoster. Two doses of recombinant ZV are recommended but not funded for individuals aged from 50 years:
Older adults over the age of 65 years are also recommended two doses of Shingrix to provide longer lasting protection. Shingrix may be offered to individuals who previously had Zostavax and/or has a history of zoster episodes. Allow 12 months between Zostavax or after an episode of zoster has resolved before giving Shingrix. There are no safety concerns around giving it sooner but since the immune system will have been activated against the varicella-zoster virus by these events, there is likely to be little additional short-term benefit for most people. Shingrix can be given sooner, from 3 months after a zoster episode has resolved or prior Zostavax dose, for individuals who are immunocompromised and at increased risk of zoster recurrence. Although Shingrix is not approved for use in under the age of 50 years in New Zealand, in situations where a specialist has recommended an adult aged 18 to 50 years to receive Shingrix, an authorised prescriber / general practitioner can provide a prescription for off-label use. Storage and preparationStore in a refrigerator (2°C – 8°C). Do not freeze. Store in the original package in order to protect from light. AdministrationGive two doses, the second dose is given 2 to 6 months after the first. The vaccine should be administered intramuscularly, only. The preferred site is into the deltoid muscle. Shingrix can be administered concurrently with other vaccines, including all National Immunisation Schedule vaccines, such as 23PPV and Tdap. Separate syringes and different injection sites should be used. The safety and efficacy of administering two liposomal adjuvanted vaccines together is not yet established. Shingrix, Fluad Quad (adjuvanted seasonal influenza vaccine) and Nuvaxovid (adjuvanted recombinant COVID-19 vaccine) may be given on the same day, at different injection-sites, if necessary but it is preferrable to allow 3 days between them or once any potential reactions have resolved. There are currently no recommendations around giving further doses or booster doses. Vaccine safetyShingrix should not be given to:
Specialist advice should be sought for the following groups: Those with bleeding disorders, such as haemophilia or thrombocytopenia. The vaccine should be administered in accordance with the haematologist’s instructions. This vaccine is for intramuscular injection only. Vaccine effectivenessDuring phase 3 clinical trials (ZOE-50 and ZOE-70), Shingrix had efficacy against both zoster and associated complications of over 90 percent efficacy in adults aged over 50 years, including those aged from 70 years and those with medical conditions that increase their risk of zoster. Pooled vaccine efficacy was 91% (95% CI 87-95) against the incidence of zoster overall and 91% (86-98% against post-herpetic neuralgia across all age groups. No decline was observed in increased age with efficacy of 91% (80-97) against zoster in those aged over 80 years. Ongoing long-term follow-up of these trial participants found efficacy against zoster plateaued after four to six years and was sustained overall at 84 percent for at least seven years post-vaccination. Post hoc analysis found the efficacy of Shingrix against zoster remained over 90% in participants with select medical conditions (eg. hypertension, diabetes, coronary heart disease, respiratory disorders). Other studies have investigated the use of Shingrix in participants aged from 18 years with severely immunocompromising conditions. Vaccine efficacy of 68.2% (95% CI 55.6-77.5%) was seen for HSCT recipients, 87.2% (44.3-98.6%) in patients with haematological malignancies and 90.5% (73.5-97.5%) for immune-mediated diseases (including psoriasis, rheumatoid arthritis and spondyloarthropathy). Efficacy against post herpetic neuralgia was 89% (22-100%) and against zoster-related hospitalisation was 85% (32-97%) in patients following HSCT. (Note, Shingrix is not yet approved for use in New Zealand under the age of 50 years). Real world effectiveness of two doses of Shingrix against zoster of 70.1% (68.6-71.5) was shown in an observational study in the US in Medicare beneficiaries aged 65 years or older. Similar effectiveness was seen for those aged over 80 years, from six or more months after vaccination and for those with autoimmune conditions. Effectiveness of two doses against post-herpetic neuralgia was 76.0% (68.4-84.8). The lower effectiveness compared with clinical trials was likely due to how zoster was notified in clinical notes as ‘suspected cases’ rather than being PCR-confirmed as in clinical trials. Last updated: Aug 2022 Which is better Shingrix or Zostavax?Shingrix (recombinant zoster vaccine) is the preferred vaccine, over Zostavax® (zoster vaccine live), a shingles vaccine in use since 2006. Zostavax may still be used to prevent shingles in healthy adults 60 years and older.
Do you need both Zostavax and Shingrix?* A shingles vaccine called zoster vaccine live (Zostavax) is no longer available for use in the United States, as of November 18, 2020. If you had Zostavax in the past, you should still get Shingrix. Talk to your healthcare provider to determine the best time to get Shingrix.
Is Zostavax discontinued?Zostavax was discontinued in the United States in November 2020. Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent. Another vaccine, known as varicella vaccine, is used to prevent diseases caused by the same virus.
...
Zoster vaccine.. Which shingles vaccine is the best?CDC recommends Shingrix as the preferred vaccine, over Zostavax, to prevent shingles and the complications from the disease. Shingrix provides stronger protection against shingles compared to Zostavax.
|